Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

5.000 +0.050 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,639,804
Open 5.000
Bid (Size) 4.900 (15)
Ask (Size) 5.050 (51)
Prev. Close 4.950
Today's Range 4.920 - 5.040
52wk Range 4.165 - 7.630
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
From MannKind
Via GlobeNewswire
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga

Performance

YTD
-24.2%
-24.2%
1 Month
-0.4%
-0.4%
3 Month
-13.6%
-13.6%
6 Month
-30.3%
-30.3%
1 Year
+14.2%
+14.2%

More News

Read More
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
From MannKind
Via GlobeNewswire
Earnings Scheduled For February 26, 2025
Via Benzinga
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
From MannKind
Via GlobeNewswire
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’
Via Stocktwits
MannKind (MNKD) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
From MannKind
Via GlobeNewswire
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
MannKind Expands Executive Leadership Team
From MannKind
Via GlobeNewswire
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Topics Stocks
Exposures US Equities
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
From MannKind
Via GlobeNewswire
MannKind Shares Are falling Today: What's Going On?
Via Benzinga
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
MannKind to Present at 2024 UBS Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
From MannKind
Via GlobeNewswire
Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference
Via Newsfile
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire

Frequently Asked Questions

Is MannKind Corporation - Common Stock publicly traded?
Yes, MannKind Corporation - Common Stock is publicly traded.
What exchange does MannKind Corporation - Common Stock trade on?
MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MannKind Corporation - Common Stock?
The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
What is the current price of MannKind Corporation - Common Stock?
The current price of MannKind Corporation - Common Stock is 5.000
When was MannKind Corporation - Common Stock last traded?
The last trade of MannKind Corporation - Common Stock was at 05/02/25 04:00 PM ET
What is the market capitalization of MannKind Corporation - Common Stock?
The market capitalization of MannKind Corporation - Common Stock is 1.32B
How many shares of MannKind Corporation - Common Stock are outstanding?
MannKind Corporation - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.